ACM
ACET icon

Altium Capital Management’s Adicet Bio ACET Stock Holding History

Altium Capital Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-9,375
Closed -$2.13M – 95
2022
Q3 		$2.13M Hold
9,375
– – 0.78% 51
2022
Q2 		$2.19M Sell
9,375
-313
-3% -$68.7K 0.88% 45
2022
Q1 		$3.1M Sell
9,688
-6,750
-41% -$1.55M 1.04% 38
2021
Q4 		$4.6M Buy
16,438
+7,545
+85% +$1.29M 1.27% 31
2021
Q3 		$1.12M Hold
8,893
– – 0.29% 91
2021
Q2 		$1.46M Hold
8,893
– – 0.34% 96
2021
Q1 		$1.86M Buy
+8,893
New +$2.04M 0.52% 85

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Altium Capital Management's ACET Position: Q4 2022 in Review

Altium Capital Management sold out of Adicet Bio (ACET) in Q4 2022, closing a stake of 9,375 shares — an estimated $2.13M sold.

Altium Capital Management first reported a position in ACET in Q1 2021 and held it in 7 quarters. The position peaked at $4.6M in Q4 2021. 100 funds tracked by Wall St. Rank hold ACET as of Q4 2022.

  • Altium Capital Management reported no remaining Adicet Bio position as of Q4 2022 after selling out during the quarter.
  • Altium Capital Management sold 9,375 Adicet Bio shares in Q4 2022, an estimated $2.13M.
  • Altium Capital Management first reported a position in Adicet Bio in Q1 2021 and held it in 7 quarters.
  • Altium Capital Management's Adicet Bio position peaked at $4.6M in Q4 2021.
  • 100 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2022.

Based on Altium Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.